<DOC>
	<DOCNO>NCT00349466</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-masked , placebo-controlled , parallel-group study adult male female , age 18 year , diagnosis moderate-to-severe keratoconjunctivitis sicca ( KCS ) . Patients randomize receive either CF101 1 mg match placebo , give orally every 12 hour ( q12h ) 12 week . A Screening Period 4 week include 2-week run-in period precede 12-week treatment period , follow 2-week follow-up period .</brief_summary>
	<brief_title>Safety Efficacy Study CF101 Treat Keratoconjunctivitis Sicca</brief_title>
	<detailed_description>At Screening Visit , patient provide write informed consent screening procedure perform , include complete medical history , medication history , physical examination , include height , weight , sit blood pressure , pulse rate temperature , clinical laboratory test . Disease activity assess use tear meniscus ( TM ) height , tear break-up time ( BUT ) , fluorescein staining ( FS ) , Schirmer test , Dry Eye Symptom Score ( DESS ) . Doses artificial tear must stable &gt; 2 week prior Screening Visit . Eligible patient begin 2-week run-in period , time instructed discontinue use topical ophthalmic medication except lubricant eye drop . Patients successfully complete 2-week run-in period randomize assigned medication ( CF101 1 mg match placebo ) take orally every q12h 12 week . Patients return assessment new supply study medication Weeks 2 , 4 , 8 12 , Week 14 final follow-up assessment .</detailed_description>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Male female , 18 year age ; Have diagnosis moderatetosevere KCS define : ( 1 ) ST ( without anesthesia ) &lt; 7 mm/5 min either eye ; AND ( 2 ) Positive FS , define corneal punctate fluorescein stain score ≥1 either eye , 0 = none 3= severe ; AND ( 3 ) At least 1 follow ocular symptom score ≥2 , 0 = none 4 = severe/interferes normal activity : photophobia , blur vision , foreign body sensation , soreness pain , itching , burning , dryness ; Willing use topical ocular treatment except unpreserved artificial tear ; Doses unpreserved artificial tear stable &gt; 2 week prior Screening Visit ; Females childbearing potential must negative urine pregnancy test screen throughout study , eligible , continue participation , study ; Females childbearing potential must willing use 2 method contraception deem adequate Investigator ( example oral contraceptive pill plus barrier method ) eligible , continue participation , study ; Ability complete study compliance protocol ; Ability understand provide write informed consent . Has Sjögren 's Syndrome significant systemic nonexocrine gland involvement ; Has StevensJohnson Syndrome ; If KCS due rheumatoid arthritis autoimmune disease , patient may receive diseasemodifying drug , include methotrexate biological agent ; Use systemic immunosuppressive drug ; Use oral corticosteroid &gt; 10 mg prednisone , equivalent , per day ; Use topical steroid within 2 week prior Screening Visit duration study ; Receipt topical cyclosporine eye drop within 3 month prior Screening Visit duration trial ; Presence chronic ocular disease KCS require topical treatment ; Presence postburn ocular injury ; Ocular herpes simplex virus infection ; Concomitant use contact lenses ; Persistent intraocular inflammation infection ; Active blepharitis ; Recent surgical occlusion lacrimal puncta ; Subepithelial corneal scarring ; Anesthetic neurotrophic cornea ; Hemoglobin level &lt; 9.0 gm/L ; Platelet count &lt; 125,000/mm^3 ; White blood cell count &lt; 3500/mm^3 ; Serum creatinine level outside laboratory 's normal limit ; Liver aminotransferase level great 2 time laboratory 's upper limit normal ; Pregnancy , plan pregnancy , lactation , inadequate contraception judge Investigator ; History malignancy within past 5 year ( exclude basal cell carcinoma skin ) ; Significant acute chronic medical , ophthalmic , psychiatric illness , judgment Investigator , could compromise patient safety , limit patient 's ability complete study , and/or compromise objective study ; Participation another investigational drug vaccine trial concurrently within 30 day ; Other condition would confound study evaluation endanger safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Keratoconjunctivitis Sicca</keyword>
	<keyword>KCS</keyword>
	<keyword>Dry Eye</keyword>
</DOC>